WHO Approves COVAXIN for Emergency Use

Geneva, The World Health Organization (WHO) has granted emergency use listing to COVAXIN, which is developed by Bharat Biotech, adding to a growing portfolio of vaccines validated by WHO for the prevention of COVID19.

The WHO Technical Advisory Group has determined that the COVAXIN vaccine meets WHO standards for protection against COVID19, that the benefit of the vaccine far outweighs risks and the vaccine can be used.

The vaccine was also reviewed by WHO’s Strategic Advisory Group of Experts on Immunization (SAGE), and recommended use of this vaccine in two doses, with a dose interval of four weeks.

The WHO disclosed that available data on vaccination of pregnant women with the COVAXIN vaccine are insufficient to assess vaccine safety or efficacy in pregnancy, adding that COVAXIN was found to have 78% efficacy against COVID19 of any severity, 14 or more days after the second dose, and is extremely suitable for low- and middle-income countries due to easy storage requirements.

Source: Saudi Press Agency